130 related articles for article (PubMed ID: 32787083)
1. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil D; Wong JF; Williams EP; Adamson RJ; Howarth A; McLeod DA; Mamai A; Kim S; Wilson BJ; Kiyota T; Aman A; Owen J; Poda G; Horiuchi KY; Kuznetsova E; Ma H; Hamblin JN; Cramp S; Roberts OG; Edwards AM; Uehling D; Al-Awar R; Bullock AN; O'Meara JA; Isaac MB
J Med Chem; 2020 Sep; 63(17):10061-10085. PubMed ID: 32787083
[TBL] [Abstract][Full Text] [Related]
2. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.
Ensan D; Smil D; Zepeda-Velázquez CA; Panagopoulos D; Wong JF; Williams EP; Adamson R; Bullock AN; Kiyota T; Aman A; Roberts OG; Edwards AM; O'Meara JA; Isaac MB; Al-Awar R
J Med Chem; 2020 May; 63(9):4978-4996. PubMed ID: 32369358
[TBL] [Abstract][Full Text] [Related]
3. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
4. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
[TBL] [Abstract][Full Text] [Related]
5. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K; Sato T; Sakai N
Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of
Murrell E; Tong J; Smil D; Kiyota T; Aman AM; Isaac MB; Watson IDG; Vasdev N
ACS Med Chem Lett; 2021 May; 12(5):846-850. PubMed ID: 34055235
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
8. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
9. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Nguyen MH; Atasoylu O; Wu L; Kapilashrami K; Pusey M; Gallagher K; Lai CT; Zhao P; Barbosa J; Liu K; He C; Zhang C; Styduhar ED; Witten MR; Chen Y; Lin L; Yang YO; Covington M; Diamond S; Yeleswaram S; Yao W
ACS Med Chem Lett; 2022 Jul; 13(7):1159-1164. PubMed ID: 35859885
[TBL] [Abstract][Full Text] [Related]
13. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
Chen J; Lin Z; Barrett L; Dai L; Qin Z
Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
[TBL] [Abstract][Full Text] [Related]
14. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
15. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Conformationally Constrained ALK2 Inhibitors.
González-Álvarez H; Ensan D; Xin T; Wong JF; Zepeda-Velázquez CA; Cros J; Sweeney MN; Hoffer L; Kiyota T; Wilson BJ; Aman A; Roberts O; Isaac MB; Bullock AN; Smil D; Al-Awar R
J Med Chem; 2024 Mar; 67(6):4707-4725. PubMed ID: 38498998
[TBL] [Abstract][Full Text] [Related]
17. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ALK2 with bicyclic pyridyllactams.
Witten MR; Wu L; Lai CT; Kapilashrami K; Pusey M; Gallagher K; Chen Y; Yao W
Bioorg Med Chem Lett; 2022 Jan; 55():128452. PubMed ID: 34780900
[TBL] [Abstract][Full Text] [Related]
19. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.
Hudson L; Mui J; Vázquez S; Carvalho DM; Williams E; Jones C; Bullock AN; Hoelder S
J Med Chem; 2018 Aug; 61(16):7261-7272. PubMed ID: 30085668
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in ALK2 Inhibitors.
Rooney L; Jones C
ACS Omega; 2021 Aug; 6(32):20729-20734. PubMed ID: 34423181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
